givinostat-hydrochloride and Melanoma

Oncogenic BRAF mutations have been widely described in melanomas and promote tumour progression and chemoresistance. We previously provided evidence that the HDAC inhibitor ITF2357 (Givinostat) targets oncogenic BRAF in SK-MEL-28 and A375 melanoma cells. Here, we show that oncogenic BRAF localises to the nucleus of these cells, and the compound decreases BRAF levels in both the nuclear and cytosolic compartments. Although mutations in the tumour suppressor

Topics: Cell Line, Tumor; Histone Deacetylase Inhibitors; Humans; Melanoma; Mutation; Proto-Oncogene Proteins B-raf; Tumor Suppressor Protein p53